An observational study in Surgical Scar and Postoperative Scar, sponsored by Nanfang Hospital, Southern Medical University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Cicatrix with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Cicatrix · China.
Among the 42 studies in Cicatrix with a site in China, this one is one of 4 that started in 2026, is one of 8 observational ones, and was the 39th registered.
616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.
Browse Cicatrix studies →8 of the 42 studies in Cicatrix with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 20–50
Mabwell (Shanghai) Bioscience Co., Ltd. · Sites in China
Ages 18+
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18+ · Women only
LIAO Peng · Sites in China
Ages 3–6
First Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages up to 80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 2
First in 2011; this study’s year is marked. 4 started in 2026.
This study's enrollment of 2,744 is above the median of 80 across 69 observational studies indexed under Cicatrix.
Median enrollment 50 across the 34 interventional studies, 119 across the 8 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 42 have an industry lead sponsor. The 10 most frequent:
Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 213 are open to participants now.
Nanfang Hospital, Southern Medical University has 1 study filed under Cicatrix — fewer than ten, so there is no comparison to draw.
4 of the studies in Cicatrix with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07576608Mabwell (Shanghai) Bioscience Co., Ltd.A Phase II Study of 9MW3811 in Patients With Pathological Scar | 2026-12 |
| NCT07608094Women's Hospital School Of Medicine Zhejiang UniversityThe Treatment Outcomes of Cesarean Scar Pregnancy | 2026-12-31 |
| NCT07620769CLASSYS Inc.Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars | 2027-03 |
| NCT07849010Peking University Third HospitalDisposable Noninvasive Skin Closure for Promoting Postoperative Wound Healing and Preventing Surgical Skin Scarring | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 42 studies in Cicatrix with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational cohort study will evaluate whether perioperative antibiotic use is associated with long-term surgical scar outcomes. The study will include adult patients who underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025 and have available surgical, medication, and scar-related clinical records.
The study will not assign participants to any treatment. Researchers will review existing medical records, perioperative antibiotic exposure, surgical characteristics, complications, and scar assessments or photographs. Scar outcomes will be assessed using modified visual analogue scale scores, scar width, scar type, and scar-related complications.
The study population will include adult patients who underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025, developed a linear surgical incision scar, and later presented to the Department of Plastic Surgery for scar-related care. Eligible patients must have available surgical records, perioperative medication records, and scar outcome information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients who underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025 and have available surgical records, perioperative medication records, and scar outcome information.
Other: Perioperative Antibiotic Exposure
Patterns of perioperative antibiotic use documented in existing medical records, including timing, indication, antibiotic type, duration, frequency, and route of administration. No antibiotic treatment will be assigned or provided by the study.
Overall Scar Appearance Score Assessed Using a Modified Visual Analogue Scale
Overall scar appearance will be evaluated from scar photographs by three blinded physicians or trained study personnel using a modified visual analogue scale. Scores range from 1 to 10, with 1 indicating appearance similar to normal skin and 10 indicating the worst imaginable scar appearance.
Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam
Scar Color Score Assessed Using a Modified Visual Analogue Scale
Scar color will be evaluated from scar photographs by three blinded physicians or trained study personnel using a modified visual analogue scale. Scores range from 1 to 10, with lower scores indicating color more similar to normal skin and higher scores indicating worse scar color.
Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam
Scar Texture Score Assessed Using a Modified Visual Analogue Scale
Scar texture will be evaluated from scar photographs by three blinded physicians or trained study personnel using a modified visual analogue scale. Scores range from 1 to 10, with lower scores indicating texture more similar to normal skin and higher scores indicating worse scar texture.
Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam
Scar Width
Scar width will be calculated from scar photographs by outlining the scar boundary and using ImageJ to measure scar area and scar length. Scar width will be calculated as scar area divided by scar length.
Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam
Scar-Related Complications
Scar-related complications will be identified from medical records and scar assessments, including wound dehiscence, suture reaction, necrosis, hematoma, infection, persistent itching, persistent pain, and sensory abnormalities.
Time frame: Postoperative days 0 to 30 (inclusive). The timing of each complication was determined from medical records.
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2026 to primary completion in Oct 2026, 2 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University →